Incidence and risk of xerosis with targeted anticancer therapies

Journal of the American Academy of Dermatology

Volumn 72, Issue 4, 2015, Pages 656-667

  Valentine, Johannah ^a   Belum, Viswanath Reddy ^b   Duran, Juanita ^c   Ciccolini, Kathryn ^b   Schindler, Katja ^b,d   Wu, Shenhong ^e,f   Lacouture, Mario E ^b  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSIDAD DEL ROSARIO   (Colombia)

^d Universitatsklinik fur Dermatologie   (Austria)

^e STONY BROOK UNIVERSITY   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

CD20; CD52; dry skin; EGFR; HDAC; HER2; incidence; Key words Bcr Abl; MEK; mTOR; Raf; risk; VEGFR; xerosis

Indexed keywords

AFATINIB; ALEMTUZUMAB; ALITRETINOIN; ANASTROZOLE; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BEXAROTENE; BORTEZOMIB; BOSUTINIB; BRENTUXIMAB VEDOTIN; CABOZANTINIB; CARFILZOMIB; CERITINIB; CETUXIMAB; CRIZOTINIB; DABRAFENIB; DACLIZUMAB; DASATINIB; DENILEUKIN DIFTITOX; DENOSUMAB; ERLOTINIB; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEFITINIB; IBRITUMOMAB TIUXETAN; IBRUTINIB; TRASTUZUMAB EMTANSINE; UNINDEXED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ENZYME INHIBITOR; HORMONE ANTAGONIST; MONOCLONAL ANTIBODY; TUMOR PROTEIN;

AGE DISTRIBUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; CONTROLLED CLINICAL TRIAL (TOPIC); DERMATOLOGIST; DRUG THERAPY; HIGH RISK PATIENT; HUMAN; INCIDENCE; MEDICAL SOCIETY; MEDLINE; MOLECULARLY TARGETED THERAPY; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SKIN MANIFESTATION; SYSTEMATIC REVIEW; WEB OF SCIENCE; XEROSIS; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPLICATION; META ANALYSIS; NEOPLASMS; PROSPECTIVE STUDY; RISK; SEVERITY OF ILLNESS INDEX; SKIN DISEASES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; ENZYME INHIBITORS; HORMONE ANTAGONISTS; HUMANS; INCIDENCE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; PROSPECTIVE STUDIES; RISK; SEVERITY OF ILLNESS INDEX; SKIN DISEASES;

EID: 84929516117     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2014.12.010     Document Type: Article

References (166)

1. M. Tiseo, M. Loprevite, and A. Ardizzoni Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer Curr Med Chem Anticancer Agents 4 2004 139 148
2. K. Soreide, M. Berg, B.S. Skudal, and B.S. Nedreboe Advances in the understanding and treatment of colorectal cancer Discov Med 12 2011 393 404
3. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 2005 341 354
4. Y. Balagula, M.E. Lacouture, and J.A. Cotliar Dermatologic toxicities of targeted anticancer therapies J Support Oncol 8 2010 149 161
5. R. Van Doorn, G. Kirtschig, E. Scheffer, T.J. Stoof, and G. Giaccone Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor Br J Dermatol 147 2002 598 601
6. N. Heidary, H. Naik, and S. Burgin Chemotherapeutic agents and the skin: an update J Am Acad Dermatol 58 2008 545 570
7. A. Joshi, S. Ortiz, and J. Witherspoon Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life Cancer 116 2010 3916 3923
8. A. Agero, S. Dusza, C. Benvenuto-Andrade, K. Busam, P. Myskowski, and A. Halpern Dermatologic side effects associated with the epidermal growth factor receptor inhibitors J Am Acad Dermatol 55 2006 657 670
9. M.E. Lacouture, and S. Lai The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome Br J Dermatol 155 2006 852 854
10. A. Osio, C. Mateus, and J.C. Soria Cutaneous side effects in patients on long-term treatment with epidermal growth factor receptor inhibitors Br J Dermatol 161 2009 515 521
11. A.C. Rosen, E.C. Case, and S.W. Dusza Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic Am J Clin Dermatol 14 2013 327 333
12. C. Ensslin, A. Rosen, S. Wu, and M.E. Lacouture Pruritus in patients treated with targeted cancer therapies: systemic review and meta-analysis J Am Acad Dermatol 69 2013 708 720
13. M. Gandhi, K. Oishi, B. Zubal, and M.E. Lacouture Unanticipated toxicities from anticancer therapies: survivors' perspectives Support Care Cancer 18 2010 1461 1468
14. A. Trotti, A.D. Colevas, and A. Setser CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 2003 176 181
15. A.P. Chen, A. Setser, and M.J. Anadkat Grading of dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0 J Am Acad Dermatol 67 2012 1025 1039
16. M. Borenstein, L. Hedges, J. Higgins, and H. Rothstein Comprehensive Meta-analysis, Version 2 2005 Biostat Englewood (NJ)
17. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
18. J. Lau, J.P. Ioannidis, and C.H. Schmid Quantitative synthesis in systematic reviews Ann Intern Med 127 1997 820 826
19. L.V. Sequist, J.C. Yang, and N. Yamamoto Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J Clin Oncol 3 2013 3327 3334
20. J.C. Yang, J.Y. Shih, and W.C. Su Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial Lancet Oncol 13 2012 539 548
21. C. Querfeld, N. Mehta, and S.T. Rosen Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center Leuk Lymphoma 50 2009 1969 1976
22. I.E. Smith, G. Walsh, and A. Skene A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer J Clin Oncol 25 2007 3816 3822
23. B.I. Rini, G. Wilding, and G. Hudes Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
24. O. Rixe, R.M. Bukowski, and M.D. Michaelson Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975 984
25. R. Govindan, J. Crowley, and L. Schwartzberg Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies J Clin Oncol 24 2006 4848 4854
26. C. Querfeld, S.T. Rosen, and J. Guitart Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma J Am Acad Dermatol 51 2004 25 32
27. R. Elisei, M.J. Schlumberger, and S.P. Müller Cabozantinib in progressive medullary thyroid cancer J Clin Oncol 31 2013 3639 3646
28. S.S. Ramalingam, J.W. Lee, and C.P. Belani Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504) J Clin Oncol 29 2011 3419 3426
29. J.A. Chan, L.S. Blaszkowsky, and P.C. Enzinger A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma Ann Oncol 22 2011 1367 1373
30. J.W. Neal, R.S. Heist, and P. Fidias Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy J Thorac Oncol 5 2010 1855 1858
31. L.D. Locati, P. Bossi, and F. Perrone Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study Oral Oncol 45 2009 574 578
32. A. Pessino, S. Artale, and S. Sciallero First-line single-agent cetuximab in patients with advanced colorectal cancer Ann Oncol 19 2008 711 716
33. A.X. Zhu, K. Stuart, and L.S. Blaszkowsky Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma Cancer 110 2007 581 589
34. J.B. Vermorken, J. Trigo, and R. Hitt Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy J Clin Oncol 25 2007 2171 2177
35. R.J. Motzer, R. Amato, and M. Todd Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma Invest New Drugs 21 2003 99 101
36. R. Wierzbicki, D.J. Jonker, and M.J. Moore A phase II, multicenter study of cetuximab monotherapy in patients with refractory metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining Invest New Drugs 29 2011 167 174
37. E.Y. Yu, G. Wilding, and E. Posadas Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer Clin Cancer Res 15 2009 7421 7428
38. J.C. Yao, M.H. Shah, and T. Ito Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
39. R.J. Motzer, B. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
40. J.C. Yao, C. Lombard-Bohas, and E. Baudin Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial J Clin Oncol 28 2010 69 76
41. M.I. Milowsky, G. Iyer, and A.M. Regazzi Phase II study of everolimus in metastatic urothelial cancer BJU Int 112 2013 462 470
42. S.R. Johnston, L.S. Kilburn, and P. Ellis Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial Lancet Oncol 14 2013 989 998
43. K. Goto, M. Nishio, and N. Yamamoto A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC) Lung Cancer 82 2013 109 114
44. H.J. Groen, M.A. Socinski, and F. Grossi A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC) Ann Oncol 24 2013 2382 2389
45. K. Yamada, K. Takayama, and S. Kawakami Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803) Jpn J Clin Oncol 43 2013 629 635
46. S.S. Ramalingam, F. Blackhall, and M. Krzakowski Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer J Clin Oncol 30 2012 3337 3344
47. E.E. Schaake, I. Kappers, and H.E. Codrington Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer J Clin Oncol 30 2012 2731 2738
48. G.V. Scagliotti, M. Krzakowski, and A. Szczesna Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial J Clin Oncol 30 2012 2070 2078
49. Y.L. Wu, J.H. Kim, K. Park, A. Zaatar, G. Klingelschmitt, and C. Ng Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study Lung Cancer 77 2012 339 345
50. T. Ciuleanu, L. Stelmakh, and S. Cicenas Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study Lancet Oncol 13 2012 300 308
51. L.V. Sequist, J. von Pawel, and E.G. Garmey Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer J Clin Oncol 29 2011 3307 3315
52. S.T. Kim, J.E. Uhm, and J. Lee Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy Lung Cancer 75 2012 82 88
53. H. Nagai, S. Tanaka, and M. Niimi Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan Int J Clin Oncol 16 2011 560 567
54. R.B. Natale, S. Thongprasert, and F.A. Greco Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 29 2011 1059 1066
55. R.S. Pruthi, M. Nielsen, and S. Heathcote A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results BJU Int 106 2010 349 354
56. W. Akerley, K.M. Boucher, J.S. Bentz, K. Arbogast, and T. Walters A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer J Thorac Oncol 4 2009 214 219
57. K. Kubota, Y. Nishiwaki, and T. Tamura Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study J Thorac Oncol 3 2008 1439 1445
58. A.M. Oza, E.A. Eisenhauer, and L. Elit Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148 J Clin Oncol 26 2008 4319 4325
59. M.N. Dickler, M.A. Cobleigh, K.D. Miller, P.M. Klein, and E.P. Winer Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer Breast Cancer Res Treat 115 2009 115 121
60. M.B. Thomas, R. Chadha, and K. Glover Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma Cancer 110 2007 1059 1067
61. L.L. Garland, C. Rankin, and D.R. Gandara Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study J Clin Oncol 25 2007 2406 2413
62. D.M. Jackman, B.Y. Yeap, and N.I. Lindeman Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer J Clin Oncol 25 2007 760 766
63. P.A. Philip, M.R. Mahoney, and C. Allmer Phase II study of erlotinib in patients with advanced biliary cancer J Clin Oncol 24 2006 3069 3074
64. A.N. Gordon, N. Finkler, and R.P. Edwards Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study Int J Gynecol Cancer 15 2005 785 792
65. P.A. Philip, M.R. Mahoney, and C. Allmer Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer J Clin Oncol 23 2005 6657 6663
66. J.W. Neal, N.A. Pennell, and B.W. Goodgame A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): toxicity evaluation J Clin Oncol 28 2010 15s [abstr 7078]
67. L. Zhang, S. Ma, and X. Song Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial Lancet Oncol 13 2012 466 475
68. F. Grossi, E. Rijavec, and M.G. Dal Bello The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib Cancer Chemother Pharmacol 69 2012 1407 1412
69. G. Joensuu, T. Joensuu, and N. Nupponen A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy Acta Oncol 51 2012 130 133
70. K. Asami, T. Koizumi, and K. Hirai Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study Clin Lung Cancer 12 2011 387 392
71. J.Y. Han, S.H. Lee, and N.J. Yoo A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer Clin Cancer Res 17 2011 1553 1560
72. D.W. Kim, S.H. Lee, and J.S. Lee A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations Lung Cancer 71 2011 65 69
73. D.H. Lee, K. Park, and J.H. Kim Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy Clin Cancer Res 16 2010 1307 1314
74. T. Mitsudomi, S. Morita, and Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
75. H. Lara-Guerra, T.K. Waddell, and M.A. Salvarrey Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer J Clin Oncol 27 2009 6229 6236
76. T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
77. R.B. Natale, D. Bodkin, and R. Govindan Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase II study J Clin Oncol 27 2009 2523 2529
78. J.S. Stewart, E.E. Cohen, and L. Licitra Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected] J Clin Oncol 27 2009 1864 1871
79. G. Goss, D. Ferry, and R. Wierzbicki Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status J Clin Oncol 27 2009 2253 2260
80. E.S. Kim, V. Hirsh, and T. Mok Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
81. L. Crinò, F. Cappuzzo, and P. Zatloukal Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study J Clin Oncol 26 2008 4253 4260
82. R. Maruyama, Y. Nishiwaki, and T. Tamura Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer J Clin Oncol 26 2008 4244 4252
83. K. Tamura, I. Okamoto, and T. Kashii Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) Br J Cancer 98 2008 907 914
84. F. Oshita, K. Yamada, H. Saito, and K. Noda Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer Cancer Chemother Pharmacol 62 2008 465 470
85. Y.M. Chen, J.M. Liu, T.Y. Chou, R.P. Perng, C.M. Tsai, and J. Whang-Peng Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy Cancer 109 2007 1821 1828
86. H. Asahina, K. Yamazaki, and I. Kinoshita A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations Br J Cancer 95 2006 998 1004
87. S. Niho, K. Kubota, and K. Goto First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study J Clin Oncol 24 2006 64 69
88. M.L. Rothenberg, B. LaFleur, and D.E. Levy Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma J Clin Oncol 23 2005 9265 9274
89. M. Tsuboi, H. Kato, and K. Nagai Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer Anticancer Drugs 16 2005 1123 1128
90. A. Polychronis, H.D. Sinnett, and D. Hadjiminas Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial Lancet Oncol 6 2005 383 391
91. D.H. Lee, J.Y. Han, and H.G. Lee Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers Clin Cancer Res 11 2005 3032 3037
92. C.M. Canil, M.J. Moore, and E. Winquist Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group J Clin Oncol 23 2005 455 460
93. M. Fukuoka, S. Yano, and G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 21 2003 2237 2246
94. M.H. Cohen, G.A. Williams, and R. Sridhara United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets Clin Cancer Res 10 2004 1212 1218
95. R.P. Dematteo, K.V. Ballman, and C.R. Antonescu Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet 373 2009 1097 1104
96. H. Joensuu, M. Eriksson, and K. Sundby Hall One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial JAMA 307 2012 1265 1272
97. R.D. Carvajal, C.R. Antonescu, and J.D. Wolchok KIT as a therapeutic target in metastatic melanoma JAMA 305 2011 2327 2334
98. M. Schlemmer, S. Bauer, and R. Schütte Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial Eur J Med Res 16 2011 206 212
99. K. Rao, S. Goodin, and M.J. Levitt A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer Prostate 62 2005 115 122
100. M. Agulnik, E.W. Cohen, and R.B. Cohen Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands J Clin Oncol 25 2007 3978 3984
101. R.C. Coombes, T. Tat, and M.L. Miller An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study) Ann Oncol 24 2013 924 930
102. P.E. Goss, I.E. Smith, and J. O'Shaughnessy Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial Lancet Oncol 14 2013 88 96
103. M. Toi, H. Iwata, and Y. Fujiwara Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies Br J Cancer 101 2009 1676 1682
104. S.S. Sridhar, S.J. Hotte, and J.L. Chin A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer Am J Clin Oncol 33 2010 609 613
105. H.J. Ross, G.R. Blumenschein Jr., and J. Aisner Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer Clin Cancer Res 16 2010 1938 1949
106. Y.E. Whang, A.J. Armstrong, and W.K. Rathmell A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer Urol Oncol 31 2013 82 86
107. S. Johnston, J. Pippen, and X. Pivot Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer J Clin Oncol 27 2009 5538 5546
108. R.C. Wadlow, A.F. Hezel, and T.A. Abrams Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab Oncologist 17 2012 14
109. K. Muro, T. Yoshino, and T. Doi A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer Jpn J Clin Oncol 39 2009 321 326
110. E. Van Cutsem, M. Peeters, and S. Siena Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer J Clin Oncol 25 2007 1658 1664
111. K.C. Bible, V.J. Suman, and J.R. Molina Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study Lancet Oncol 11 2010 962 972
112. F.M. Iwamoto, K.R. Lamborn, and H.I. Robins Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02) Neuro Oncol 12 2010 855 861
113. A. Grothey, E. Van Cutsem, and A. Sobrero Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 303 312
114. R.J. Motzer, B. Escudier, and P. Tomczak Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Lancet Oncol 14 2013 552 562
115. T.J. Herzog, G. Scambia, and B.G. Kim A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma Gynecol Oncol 130 2013 25 30
116. A.M. Dingemans, W.W. Mellema, and H.J. Groen A phase II study of sorafenib in patients with platinum-pretreated, advanced (stage IIIb or IV) non-small cell lung cancer with a KRAS mutation Clin Cancer Res 19 2013 743 751
117. H.A. Wakelee, J.W. Lee, N.H. Hanna, A.M. Traynor, D.P. Carbone, and J.H. Schiller A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501 J Thorac Oncol 7 2012 1574 1582
118. E.T. Lam, M.D. Ringel, and R.T. Kloos Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer J Clin Oncol 28 2010 2323 2330
119. S. Pacey, M.J. Ratain, and K.T. Flaherty Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a phase II randomized discontinuation trial Invest New Drugs 29 2011 481 488
120. G. Bianchi, S. Loibl, and C. Zamagni Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer Anticancer Drugs 20 2009 616 624
121. G.R. Blumenschein Jr., U. Gatzemeier, and F. Fossella Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer J Clin Oncol 27 2009 4274 4280
122. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
123. R.T. Kloos, M.D. Ringel, and M.V. Knopp Phase II trial of sorafenib in metastatic thyroid cancer J Clin Oncol 27 2009 1675 1684
124. B. Escudier, C. Szczylik, and T.E. Hutson Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280 1289
125. A. Moreno-Aspitia, R.F. Morton, and D.W. Hillman Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336 J Clin Oncol 27 2009 11 15
126. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
127. W.L. Dahut, C. Scripture, and E. Posadas A phase II clinical trial of sorafenib in androgen-independent prostate cancer Clin Cancer Res 14 2008 209 214
128. K.N. Chi, S.L. Ellard, and S.J. Hotte A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer Ann Oncol 19 2008 746 751
129. C. Elser, L.L. Siu, and E. Winquist Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma J Clin Oncol 25 2007 3766 3773
130. R.C. Kane, A.T. Farrell, and H. Saber Sorafenib for the treatment of advanced renal cell carcinoma Clin Cancer Res 12 2006 7271 7278
131. J.R. Strosberg, J.M. Weber, and J. Choi A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors Ann Oncol 23 2012 2335 2341
132. N.G. Chau, S.J. Hotte, and E.X. Chen A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC Ann Oncol 23 2012 1562 1570
133. B. Escudier, J. Roigas, and S. Gillessen Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4068 4075
134. S. Faivre, E. Raymond, and E. Boucher Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study Lancet Oncol 10 2009 794 800
135. A.X. Zhu, D.V. Sahani, and D.G. Duda Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study J Clin Oncol 27 2009 3027 3035
136. M.A. Socinski, S. Novello, and J.R. Brahmer Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer J Clin Oncol 26 2008 650 656
137. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
138. V.E. Kwitkowski, T.M. Prowell, and A. Ibrahim FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma Oncologist 15 2010 428 435
139. I. Duran, J. Kortmansky, and D. Singh A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Br J Cancer 95 2006 1148 1154
140. A.M. Oza, L. Elit, and M.S. Tsao Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group J Clin Oncol 29 2011 3278 3285
141. K.B. Kim, R. Kefford, and A.C. Pavlick Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor J Clin Oncol 31 2013 482 489
142. J.S. Ahn, K.H. Lee, and J.M. Sun A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy Lung Cancer 82 2013 455 460
143. S.A. Wells Jr., B.G. Robinson, and R.F. Gagel Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial J Clin Oncol 30 2012 134 141
144. K. Kiura, K. Nakagawa, and T. Shinkai A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer J Thorac Oncol 3 2008 386 393
145. M. Kirschbaum, P. Frankel, and L. Popplewell Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma J Clin Oncol 29 2011 1198 1203
146. R.M. Giusti, K.A. Shastri, M.H. Cohen, P. Keegan, and R. Pazdur FDA drug approval summary: panitumumab (Vectibix) Oncologist 12 2007 577 583
147. J.Y. Douillard, S. Siena, and J. Cassidy Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
148. J. Thaler, M. Karthaus, and L. Mineur Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study BMC Cancer 12 2012 438
149. H. Bergman, T. Walton, and R. Del Bel Managing skin toxicities related to panitumumab J Am Acad Dermatol 71 2014 754 759
150. M.E. Lacouture Mechanisms of cutaneous toxicities to EGFR inhibitors Nat Rev Cancer 6 2006 803 812
151. J. Albanell, F. Rojo, and S. Averbuch Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition J Clin Oncol 20 2002 110 124
152. B.M. Lichtenberger, P.A. Gerber, and M. Holcmann Epidermal EGFR controls cutaneous host defense an prevents inflammation Sci Transl Med 5 2013 199ra111
153. T. Sugawara, N. Iwamoto, and M. Akashi Tight junction dysfunction in the stratum granulosum leads to aberrant stratum corneum barrier function in claudin-1-deficient mice J Dermatol Sci 70 2013 12 18
154. K.T. Flaherty, C. Robert, and P. Hersey Improved survival with MEK inhibition in BRAF-mutated melanoma N Engl J Med 367 2012 107 114
155. R. Anforth, M. Liu, and B. Nguyen Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib Australas J Dermatol 55 2014 250 254
156. T. Lynch, E. Kim, B. Eaby, J. Garey, D. West, and M.E. Lacouture Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management Oncologist 12 2007 610 621
157. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291 3310
158. J. Folkman Role of angiogenesis in tumor growth and metastasis Semin Oncol 29 2002 15 18
159. L.F. Brown, K.T. Yeo, and B. Berse Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing J Exp Med 176 1992 1375 1379
160. R.M. Van Geel, J.H. Beijnen, and J.H. Schellens Concise drug review: pazopanib and axitinib Oncologist 17 2012 1081 1089
161. R. Eilers, M. Gandhi, and J. Patel Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy J Natl Cancer Inst 102 2010 47 53
162. L. Zhang, Q. Zhou, L. Ma, Z. Wu, and Y. Wang Meta-analysis of dermatological toxicities associated with sorafenib Clin Exp Dermatol 36 2011 344 350
163. D. Lipster, K. Kragballe, and J.H. Saurat Other topical medications J.L. Bolognia, J.L. Jorizzo, R.P. Rapini, Dermatology 1st ed. 2003 Elsevier Limited Philadelphia (PA) 2062
164. A.V. Rawlings, A. Davies, and M. Carlomusto Effect of lactic acid isomers on keratinocyte ceramide synthesis, stratum corneum lipid levels and stratum corneum barrier function Arch Dermatol Res 288 1996 383 390
165. E.J. Van Scott, and R.J. Yu Hyperkeratinization, corneocyte cohesion, and alpha hydroxy acids J Am Acad Dermatol 11 1984 867 879
166. Y. Kiyohara, N. Yamazaki, and A. Kishi Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer J Am Acad Dermatol 69 2013 463 472